Jason Tardio
COO & PresidentMr. Jason Tardio, M.B.A. serves as Chief Operating Officer and President of Immunic, Inc since July 12, 2024. He served as Chief Operating Officer of Ovid Therapeutics Inc. since June 2021 until July 11, 2024 and served as its Chief Commercial Officer since November 2019 until June 2021. Prior to joining Ovid in 2019, Mr. Tardio served as Vice President and Head of the Multiple Sclerosis franchise at Novartis. Prior to Novartis, Mr. Tardio held roles of increasing responsibility at Biogen where he served as GM, Managing Director for Biogen's Latin America South affiliate, leading the business for Argentina, Chile and Uruguay. At Biogen, Mr. Tardio held a wide range of sales and marketing roles of increasing responsibility, including positions in Global Commercial Strategy, the U.S. Business Unit and at the international affiliate level. He has many years of commercial experience in the biopharmaceutical industry began at Wyeth and Sepracor, with roles in sales, sales training and marketing. Mr. Tardio holds a Bachelor of Science from The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph's University.
Positions
- Company NameImmunic, Inc.Stock CodeIMUXPositionCOO & PresidentColleagues
- MWMichael Weston BonneyChair of the Board
- GWGlenn WhaleyChief Financial Officer
- ELErik LundgrenCEO & Director
- HKHella KohlhofCo-Founder & Chief Scientific Officer
- JBJessica BreuVice President of Investor Relations & Communications
- JNJorg NeermannIndependent Director
- BABarclay A. PhillipsLead Independent Director
- JCJon CongletonIndependent Director
